OR WAIT null SECS
September 19, 2023
Anemia, experienced by most myelofibrosis patients, has caused over 30% of patients to discontinue their treatment.
Experts discussed how to transform companies into learning organizations at the 2023 PDA/FDA Joint Regulatory Conference.
Iopofosine provides targeted delivery of idodine-131 directly to cancer cells.
September 18, 2023
The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.
The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.
September 15, 2023
The safety profile of erdafitinib observed in THOR was consistent with the previously reported safety profile of erdafitinib in metastatic urothelial carcinoma (mUC).
According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.
September 11, 2023
Topiramate can cause serious birth defects if exposed to children in the womb.
September 08, 2023
The new policy will require trading partners to supply, accept, and manage all documentation of product and ownership of prescription drugs electronically.
September 02, 2023
European vaccine manufacturing is being boosted with high level investments.